Cargando…

CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity

CRM1/XPO1 (CRM1) is a nuclear export chaperone that mediates the export of proteins essential to growth regulation and tumor suppression. Its overexpression in tumors was found to be associated with poor prognosis. Selective inhibitors of nuclear export are in phase I and II clinical trials for seve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saulino, David M., Younes, Pamela S., Bailey, Jennifer M., Younes, Mamoun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940369/ https://www.ncbi.nlm.nih.gov/pubmed/29765539 http://dx.doi.org/10.18632/oncotarget.25088

Ejemplares similares

Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma
por: Younes, Mamoun, et al.
Publicado: (2018)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Pancreatic stromal Gremlin 1 expression during pancreatic tumorigenesis
por: Davis, Joy M., et al.
Publicado: (2020)

Specific inhibition of the Survivin–CRM1 interaction by peptide-modified molecular tweezers
por: Meiners, Annika, et al.
Publicado: (2021)

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
por: Liu, Xuejiao, et al.
Publicado: (2016)

XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
por: Pan, Lijia, et al.
Publicado: (2021)

Reduced Selenium-Binding Protein 1 in Breast Cancer Correlates with Poor Survival and Resistance to the Anti-Proliferative Effects of Selenium
por: Zhang, Sheng, et al.
Publicado: (2013)

Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells
por: Yang, Jennifer, et al.
Publicado: (2014)

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

IFI27/ISG12 Downregulates Estrogen Receptor α Transactivation by Facilitating Its Interaction With CRM1/XPO1 in Breast Cancer Cells
por: Cervantes-Badillo, Mayte Guadalupe, et al.
Publicado: (2020)

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma
por: Vay, Christian, et al.
Publicado: (2022)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD)
por: Younes, Mamoun, et al.
Publicado: (2022)

The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells
por: Zhang, Jing, et al.
Publicado: (2022)

Survivin expression and serum levels in pancreatic cancer
por: Dong, He, et al.
Publicado: (2015)

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma
por: Sarela, A I, et al.
Publicado: (2002)

Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression
por: Chaichanasak, Nadda, et al.
Publicado: (2018)

Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas
por: Sumi, Toshiyuki, et al.
Publicado: (2018)

Survivin expression and its clinical significance in pancreatic cancer
por: Lee, Myung Ah, et al.
Publicado: (2005)

Expression of Survivin and Cortactin in Colorectal Adenocarcinoma: Association with Clinicopathological Parameters
por: Lee, Ying-Yu, et al.
Publicado: (2009)

Role of Napsin A and Survivin Immunohistochemical Expression in Bronchogenic Adenocarcinoma
por: Mohammed Salama, Maha Elsayed
Publicado: (2020)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Correlation of CRM1-NES affinity with nuclear export activity
por: Fu, Szu-Chin, et al.
Publicado: (2018)

Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma
por: Yan, Li, et al.
Publicado: (2020)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor
por: Sui, Min, et al.
Publicado: (2021)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells
por: Konopka, Krystyna, et al.
Publicado: (2008)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
por: Fisher, Jack G., et al.
Publicado: (2023)

Expression and clinical correlation of Survivin and PTEN in gastric cancer patients
por: Yusufu, Aikeremu, et al.
Publicado: (2020)

Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2017)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

The Survivin −31 Snp in Human Colorectal Cancer Correlates with Survivin Splice Variant Expression and Improved Overall Survival
por: Antonacopoulou, Anna G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ccrcvcqdad6v106barv65pm6qk